

Contents

The pharmacokinetics of nitroglycerin, with particular reference to Nitroderm TTS by W. RIESS, S. BRECHBÜHLER, P. FANKHAUSER, A. GÉRARDIN, P. IMHOF, and J. MOPPERT	9
Discussion: W. RIESS / R. RØDE / S. SHUSTER	22
Haemodynamic changes induced over 24 hours by two different doses of transdermal nitroglycerin: a double-blind, placebo-controlled study in coronary patients by A. REALE, M. MOTOLESE, and F. ROMEO	24
Haemodynamic effects of transdermal nitroglycerin in patients with coronary heart disease by H. W. WIECHMANN	29
Discussion: M. BASSAN / A. REALE / D.N. SHARPE / B. WOODCOCK	33
A comparative study of transdermal nitroglycerin versus placebo in the treatment of stable angina pectoris by K. MIDTBØ	35
Anti-anginal efficacy of transdermal nitroglycerin: assessment by a double-blind, randomised, cross-over trial by BALA SUBRAMANIAN, N.S. KHURMI, M.J. O'HARA, M.J. BOWLES, and E.B. RAFTERY	42
Influence of transdermal nitroglycerin on exercise capacity in patients with stable angina pectoris by M.A.B. NAAFS, A.C. DE BOER, R.W. KOSTER, C.W. KLAZEN, and A.J. DUNNING	47
Discussion: W.-D. BUSSMANN / M. FERRATINI / H. LETZEL / J.P. ROOS / BALA SUBRAMANIAN / A. ZANCHETTI	54
Haemodynamic effects of transdermal nitroglycerin in acute myocardial infarction by S.H. TAYLOR, S.P. VERMA, B. SILKE, G. REYNOLDS, and N.C. JACKSON	56
Discussion: W.-D. BUSSMANN / A. GOLDBERG / D.N. SHARPE / S.H. TAYLOR / A. ZANCHETTI	63
Concluding remarks by W.-D. BUSSMANN	66